SMAD2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.
Drosophila, homolog of, MADR2, HsMAD2, JV18, JV18-1, MAD homolog 2, MADH2, MADR2, MGC22139, MGC34440, Mad-related protein 2, Mother against DPP homolog 2, Mothers against DPP homolog 2, Mothers against decapentaplegic homolog 2, Mothers against decapentaplegic, Drosophila, homolog of, 2, OTTHUMP00000163489, SMAD family member 2, SMAD, mothers against DPP homolog 2, SMAD2_HUMAN, Sma and Mad related protein 2, Sma- and Mad-related protein 2 MAD, hMAD-2
SMAD2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and 1 bp insertion in exon2.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Smad2 also known as Mothers against decapentaplegic homolog 2 (MAD2) or MADR2 is a signaling protein involved in the transforming growth factor-beta (TGF-β) receptor pathway. Smad2 has a molecular mass of approximately 58 kDa and expresses in various tissues including epithelial mesenchymal and endothelial cells. Smad2 undergoes phosphorylation on serine residues in response to TGF-β signaling converting it into phosphorylated forms often referred to as p-Smad2 or phospho-Smad2. These phosphorylated forms are critical for the relay of signals from the cell surface to the nucleus.
Smad2 acts as an intracellular mediator for TGF-β signaling a pathway important for regulating cell proliferation differentiation and apoptosis. Smad2 typically functions as part of a heteromeric complex with Smad4 another key player in TGF-β signaling. Upon activation phosphorylated Smad2 combines with Smad4 to form a complex that translocates into the nucleus. This complex then binds to specific DNA sequences to regulate the transcription of target genes involved in processes such as cell growth inhibition and extracellular matrix production.
Smad2 is integral to the TGF-β and activin receptor signaling pathways. These pathways are essential in controlling cell growth and immune responses. Smad2 interacts with other proteins such as Smad3 in addition to Smad4 to modulate gene expression effectively. The interaction between Smad2 and these proteins ensures precise control of cellular responses to external stimuli emphasizing its pivotal role in maintaining cellular homeostasis.
Smad2 correlates with various pathological conditions including fibrosis and cancer. Aberrant Smad2 signaling can contribute to the development of these diseases as excessive TGF-β signaling promotes fibrotic tissue deposition and tumor progression. Smad2 connects with other proteins like Smad3 in these pathological contexts both acting as mediators of abnormal cellular behaviors. Understanding the regulatory mechanisms of Smad2 can help develop therapeutic strategies against disorders linked to dysregulated TGF-β signaling.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBS
Lane 1: Wild-type HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate, 20 ug
Lane 2: Wild-type HeLa (human cervix adenocarcinoma epithelial cell) treated with 20 ng/ml TGF beta1 for 15 minutes, whole cell lysate, 20 ug
Lane 3: Smad2 knockout HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate, 20 ug
Lane 4: Smad2 knockout HeLa (human cervix adenocarcinoma epithelial cell), treated with 20 ng/ml TGF beta1 for 15 minutes, whole cell lysate, 20 ug
Lanes 1-4: Merged signal (red and green). Green - Anti-Smad2 (phospho S467) antibody [EPR23681-40] ab280888 observed at 60 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse monoclonal [6C5] to GAPDH) observed at 36 kDa.
Anti-Smad2 (phospho S467) antibody [EPR23681-40] ab280888 Anti-Smad2 (phospho S467) antibody [EPR23681-40] was shown to specifically react with Smad2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human SMAD2 knockout HeLa cell line ab255430 (knockout cell lysate ab263833) was used. Wild-type and Smad2 knockout samples were subjected to SDS-PAGE.
Anti-Smad2 (phospho S467) antibody [EPR23681-40] ab280888 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated at 4℃ overnight at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Smad2 (phospho S467) antibody [EPR23681-40] (Anti-Smad2 (phospho S467) antibody [EPR23681-40] ab280888) at 1/1000 dilution
Lane 1: Wild-type HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate at 20 µg
Lane 2: Wild-type HeLa (human cervix adenocarcinoma epithelial cell) treated with 20 ng/ml TGF beta1 for 15 minutes, whole cell lysate at 20 µg
Lane 3: Smad2 knockout HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate at 20 µg
Lane 4: Smad2 knockout HeLa (human cervix adenocarcinoma epithelial cell), treated with 20 ng/ml TGF beta1 for 15 minutes, whole cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG H&L (IRDye® 800CW) (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat Anti-Mouse IgG H&L (IRDye® 680RD) (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution
Predicted band size: 52 kDa
Observed band size: 60 kDa
Lane 2: Jurkat cell lysate (20 μg)
Lane 3: Wild-type HeLa cell lysate (20 μg)
Lane 4: SMAD2 knockout HeLa cell lysate (20 μg)
Lanes 1 - 4: Merged signal (red and green). Green - Anti-Smad2 antibody [EP567Y] ab33875 observed at 58 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Smad2 antibody [EP567Y] ab33875 was shown to react with Smad2 in wild-type HeLa. Loss of signal was observed when knockout cell line Human SMAD2 knockout HeLa cell line ab255430 (knockout cell lysate ab263833) was used. Wild-type and Smad2 knockout samples were subjected to SDS-PAGE. Anti-Smad2 antibody [EP567Y] ab33875 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Smad2 antibody [EP567Y] (Anti-Smad2 antibody [EP567Y] ab33875) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: Jurkat cell lysate at 20 µg
Lane 2: Western blot - Human SMAD2 knockout HeLa cell line (Human SMAD2 knockout HeLa cell line ab255430)
Lane 3: Wild-type HeLa cell lysate at 20 µg
Lane 4: SMAD2 knockout HeLa cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 52 kDa
Observed band size: 37 kDa, 58 kDa
Lane 2: Jurkat cell lysate (20 μg)
Lane 3: Wild-type HeLa cell lysate (20 μg)
Lane 4: SMAD2 knockout HeLa cell lysate (20 μg)
Lanes 1 - 4: Merged signal (red and green). Green - Anti-Smad2 antibody [EP784Y] ab40855 observed at 58 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Smad2 antibody [EP784Y] ab40855 was shown to react with Smad2 in wild-type HeLa. Loss of signal was observed when knockout cell line Human SMAD2 knockout HeLa cell line ab255430 (knockout cell lysate ab263833) was used. Wild-type and Smad2 knockout samples were subjected to SDS-PAGE. Anti-Smad2 antibody [EP784Y] ab40855 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 2000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Smad2 antibody [EP784Y] (Anti-Smad2 antibody [EP784Y] ab40855) at 1/2000 dilution
Lane 1: A549 cell lysate at 20 µg
Lane 2: Jurkat cell lysate at 20 µg
Lane 2: Western blot - Human SMAD2 knockout HeLa cell line (Human SMAD2 knockout HeLa cell line ab255430)
Lane 3: Wild-type HeLa cell lysate at 20 µg
Lane 4: SMAD2 knockout HeLa cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Predicted band size: 52 kDa
Observed band size: 37 kDa, 55 kDa
Allele-2: 1 bp insertion in exon2
Allele-1: 1 bp deletion in exon2
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com